MediCult to conduct Proof-of-Concept Study for Novo Nordisk

MediCult A/S and Novo Nordisk A/S have signed an agreement whereby MediCult shall perform in vitro proof-of-concept studies, with the aim of proving the concept and identifying potential dose range. Novo Nordisk shall supply active follicular fluid meiosis activating sterol, FF-MAS, for the studies.

The agreement provides MediCult with an option to negotiate a license agreement. Payment will be made in the form of 200,000 MediCult shares. Novo Nordisk has informed MediCult that it views the compensation in MediCult shares as being purely financial, and that it has no intention of becoming a long-term shareholder of MediCult. The shares are freely tradable.

MediCult has established a strong platform for in vitro maturation, IVM, through launch of its IVM System in December 2003 along with a partnership concept focused on training clinics for the new procedure. Pregnancy rates of IVM have improved over the last couple of years. Further improvement of the oocyte maturation procedure and media is required to move pregnancy rates of IVM even closer to those of traditional in vitro fertilisation, IVF.

IVM infertility treatment without hormone injections - significantly improves the convenience for women undergoing infertility treatment. Single embryo transfer will be implemented as a result of increased success rates within IVF. Birth of multiplets associated with possible medical, social and economical problems will thus be avoided. Mimicking nature in culture media will provide the right conditions for the in vitro process of fertilization, gene expression and embryo development, i.e. a healthy growth of the child.

For further information please contact:

Jesper Funding Andersen

CEO

Tel: +45 46 79 02 00

Email: medicult@medicult.com

Or visit: www.medicult.com